- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 20117/10/07 6:45 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent (Irish Patent Number 60014) expires in November 2011. “more...
7/9/07 12:44 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) has been notified of an unsolicited “mini-tender offer” by TRC Capital Corporation of Toronto (TRC) for TRC to purchase in cash up to four million shares, or approximately 0.057%, of the outstanding Pfizer common stock, at a price of $25.00 per share. TRC’s offer price of $25.00 per Pfizer share represents a 2.31% discount to the closing price on June 26, 2007, the day before themore...
7/3/07 1:50 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Wednesday, July 18. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2007 Performance Report, to be issued that morning. To listen to the webcast and view the Performance Report, visit our web sitemore...
6/30/07 5:00 am EDT
New Data Reinforce Importance of Irinotecan Regimen in First Line SettingBARCELONA--(BUSINESS WIRE)--Data presented for the first time in Europe reinforce the position of irinotecan as a key component of first line therapy in the management of patients with metastatic colorectal cancer (mCRC). Colorectal cancer is the most common cancer in Europe, and the third most common cancer worldwide. Each year, 138,000 Europeans die from the disease. However, colorectal cancer is preventable in most cases and highlymore...
6/28/07 9:18 am EDTNEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer today declared a 29-cent third-quarter, 2007, dividend on the company's common stock, payable September 5, 2007, to shareholders of record at the close of business on August 10, 2007 Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The third-quarter 2007 cashmore...
Pfizer Board of Directors to Initiate Face-to-Face Meetings with Company's Institutional Investors on Corporate Governance Policies and Practices6/28/07 9:10 am EDT
Commitment Enhances Long-Standing Focus on Highest Governance StandardsNEW YORK--(BUSINESS WIRE)--Pfizer said today that members of its Board of Directors will invite its largest institutional shareholders to a meeting where they will have an opportunity to provide comments and perspective on the company’s governance policies and practices including executive compensation. Pfizer is the first company to initiate a regular meeting between its Board and institutional investors on governance. The Board will invitemore...
Pfizer Initiates Phase III Trial to Study Sunitinib Malate in Patients with Metastatic Colorectal Cancer6/28/07 3:00 am EDT
New Phase I Data Evaluating Sunitinib Malate in Patients with Metastatic Colorectal Cancer Presented at the World Congress on Gastrointestinal CancerBARCELONA, Spain--(BUSINESS WIRE)--Pfizer announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of sunitinib malate, in combination with a standard chemotherapy regimen, in patients with metastatic colorectal cancer (mCRC) - cancer originating in the colon that has spread to other parts of the body. In addition, new data from a Phase I study being presented this week at the World Congress on Gastrointestinalmore...
Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke6/25/07 10:06 am EDTCHICAGO--(BUSINESS WIRE)--Pfizer announced today that Lipitor (atorvastatin calcium) Tablets 80 mg reduced the risk of stroke, coronary heart disease events and major coronary events in type 2 diabetes patients who had no known coronary heart disease but who had experienced a recent stroke or mini-stroke, compared with placebo. The results are from a new analysis of the landmark Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)more...
6/23/07 11:00 am EDTCHICAGO--(BUSINESS WIRE)--Results from three-year interim analyses of two ongoing long-term clinical trials showed that small mean declines in lung function in diabetes patients who took Exubera® (insulin human [rDNA origin]) Inhalation Powder reversed when Exubera was discontinued. Upon re-initiation of Exubera, lung function changes similar to first time users of Exubera were observed. The studies also showed that patients on an Exuberamore...
6/21/07 4:03 pm EDT
First FDA-Approved Medicine for Fibromyalgia Represents
Treatment Advance for Millions of Americans Suffering From This Chronic, Widespread Pain ConditionNEW YORK--(BUSINESS WIRE)--Pfizer announced today that the Food and Drug Administration (FDA) approved Lyrica® (pregabalin) capsules CV for the management of fibromyalgia, one of the most common chronic, widespread pain conditions in the United States. The approval of Lyrica, which received a priority review, represents a breakthrough for the more than six million Americans who suffer from this debilitating condition who previously had no FDAmore...